Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10683885 | 0.87 | — | — | |
| SCHEMBL734892 | 0.87 | — | — | |
| SCHEMBL10271864 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL10687809 | 0.85 | NCF1 (0.46) | NCF1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9437326 | 0.85 | NCF1 (0.46) | NCF1SMN1; SMN2 | |
| SCHEMBL2425235 | 0.84 | DRD2 (0.47) | NCF1DRD2DRD3 | |
| Trifluoroacetic Acid SCHEMBL5791449 | 0.84 | DPP8 (0.40) | CHRM5CCR2KCNH2SMN1; SMN2HSD11B1 | |
| SCHEMBL9926453 | 0.83 | BCHE (0.40) | DRD2DRD3CHRM5ADRA2CCCR2 | |
| SCHEMBL12718219 | 0.83 | BCHE (0.40) | DRD2DRD3CHRM5ADRA2CCCR2 | |
| SCHEMBL12718204 | 0.83 | BCHE (0.40) | DRD2DRD3CHRM5ADRA2CCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908953-B2 | Crosslinker-accelerator system for polyacrylates | TESA SE (DE) | 2018-03-06 | — | — | US | claimed |
| EP-2617789-B1 | Crosslinking accelerator system for polyacrylates | TESA SE (DE) | 2014-12-17 | — | — | EP | claimed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2023121971-A1 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BEAM THERAPEUTICS INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2019148136-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| EP-3054955-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9908953-B2 | Crosslinker-accelerator system for polyacrylates | TESA SE (DE) | 2018-03-06 | — | — | US | disclosed |
| US-9790221-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| WO-2016081679-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | WO | disclosed |
| EP-2617789-B1 | Crosslinking accelerator system for polyacrylates | TESA SE (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-20130190457-A1 | Crosslinker-Accelerator System for Polyacrylates | TESA SE (DE) | 2013-07-25 | — | — | US | disclosed |
| EP-2617789-A1 | Crosslinking accelerator system for polyacrylates | tesa SE (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20060142312-A1 | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones | PFIZER INC | 2006-06-29 | — | — | US | disclosed |
| EP-0626373-B1 | Quinazolinone derivatives | SUMITOMO PHARMA (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5556860-A | ANTIISCHEMIC AGENTS, BRAIN DISORDERS AND BLOOD METAL CONCENTRATIONS AND KIDNEY DISEASE | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0626373-A1 | Quinazolinone derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142312-A1 | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones | CDK4, CDK2, CCNA1 | NCF1 3058/4885KDM4E 450/4885DRD2 941/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | NCF1 283/4885KDM4E 674/4885DRD2 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.